AR108461A1 - IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT - Google Patents
IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENTInfo
- Publication number
- AR108461A1 AR108461A1 ARP170101261A ARP170101261A AR108461A1 AR 108461 A1 AR108461 A1 AR 108461A1 AR P170101261 A ARP170101261 A AR P170101261A AR P170101261 A ARP170101261 A AR P170101261A AR 108461 A1 AR108461 A1 AR 108461A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- pharmaceutically acceptable
- acceptable salts
- formula
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta memoria descriptiva se refiere generalmente a los compuestos de la fórmula (1), y sus sales farmacéuticamente aceptables, en la cual R¹ es 4-flúor piperidin-1-il o 3-flúor pirrolidin-1-il y R² es metilo o hidro; el uso de los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables para tratar o prevenir una enfermedad mediada por ATM, incluyendo cáncer; composiciones farmacéuticas que comprenden compuestos sustituidos imidazo[4,5-c]quinolin-2-ona o sus sales farmacéuticamente aceptables; estuches que comprenden los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables; métodos para la fabricación de los compuestos de la fórmula (1) o sus sales farmacéuticamente aceptables; e intermedios útiles en tal fabricación.This specification generally refers to the compounds of the formula (1), and their pharmaceutically acceptable salts, in which R¹ is 4-fluorine piperidin-1-yl or 3-fluorine pyrrolidin-1-yl and R² is methyl or hydro ; the use of the compounds of the formula (1) or their pharmaceutically acceptable salts to treat or prevent an ATM-mediated disease, including cancer; pharmaceutical compositions comprising imidazo [4,5-c] quinolin-2-one substituted compounds or their pharmaceutically acceptable salts; kits comprising the compounds of the formula (1) or their pharmaceutically acceptable salts; methods for manufacturing the compounds of the formula (1) or their pharmaceutically acceptable salts; and intermediates useful in such manufacturing.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608227.3A GB201608227D0 (en) | 2016-05-11 | 2016-05-11 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108461A1 true AR108461A1 (en) | 2018-08-22 |
Family
ID=56297492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170101261A AR108461A1 (en) | 2016-05-11 | 2017-05-11 | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR108461A1 (en) |
| GB (1) | GB201608227D0 (en) |
| TW (1) | TW201805284A (en) |
| WO (1) | WO2017194632A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110386932A (en) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | For the dual ATM and DNA-PK inhibitor in antitumor therapy |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CA3111994A1 (en) * | 2018-09-14 | 2020-03-19 | Suzhou Zanrong Pharma Limited | 1-isopropyl-3-methyl-8-(pyridin-3-yl)-1,3-dihydro-2h-imidazo[4,5-c]cinnolin-2-one as selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
| EP3845532B1 (en) * | 2018-09-30 | 2022-12-21 | Medshine Discovery Inc. | Quinolino-pyrrolidin-2-one derivative and application thereof |
| WO2021098734A1 (en) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | Substituted quinolinopyrrolidone compound as atm inhibitor and application thereof |
| WO2021139814A1 (en) * | 2020-01-09 | 2021-07-15 | 南京明德新药研发有限公司 | Quinoline imidazole compound and application thereof |
| WO2021197339A1 (en) * | 2020-03-30 | 2021-10-07 | 南京明德新药研发有限公司 | Crystal form of quinopyrrolidine-2-one compound serving as atm inhibitor and use thereof |
| WO2021260580A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| WO2023143282A1 (en) * | 2022-01-26 | 2023-08-03 | 正大天晴药业集团股份有限公司 | Hydrazino group-containing compound |
| CN115778962A (en) * | 2022-11-28 | 2023-03-14 | 中国医学科学院肿瘤医院 | Medicine for treating male esophageal cancer patient and related application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| DE69709319T2 (en) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab | 4-ANILINOQUINAZOLINE DERIVATIVES |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| CN102372711B (en) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | Imidazo quinoline PI3K and mTOR (mammalian target of rapamycin) dual inhibitor |
| CN102399218A (en) | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | Triheterocyclic compounds and their use as PI3K inhibitors |
| NO2714752T3 (en) * | 2014-05-08 | 2018-04-21 | ||
| GB201516504D0 (en) * | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
-
2016
- 2016-05-11 GB GBGB1608227.3A patent/GB201608227D0/en not_active Ceased
-
2017
- 2017-05-10 WO PCT/EP2017/061229 patent/WO2017194632A1/en active Application Filing
- 2017-05-10 TW TW106115396A patent/TW201805284A/en unknown
- 2017-05-11 AR ARP170101261A patent/AR108461A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201608227D0 (en) | 2016-06-22 |
| WO2017194632A1 (en) | 2017-11-16 |
| TW201805284A (en) | 2018-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR108461A1 (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT | |
| CO2018003969A2 (en) | Imidazo [4,5-c] quinolin-2-one compounds | |
| DOP2018000115A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE IN CANCER TREATMENT | |
| PE20191474A1 (en) | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| DOP2016000281A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
| DOP2018000065A (en) | DERIVATIVES OF 8- [6- [3- (AMINO) PROPOXI] -3-PIRIDIL] 1-ISOPROPILIMIDAZO [4,5-C] QUINOLIN-2-ONA AS SELECTED MODULATORS OF THE MUTED TELANGIECTASIA ATAXIA KINASE (ATM) FOR THE CANCER TREATMENT | |
| CL2019001077A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo [4,3-f] isoquinoline derivatives useful in the treatment of cancer. | |
| CO2017002998A2 (en) | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein | |
| CO2017004525A2 (en) | Ror-gamma inhibitory dihydropyrrolopyridines | |
| CR20150628A (en) | DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES | |
| AR102981A1 (en) | INHIBITORS OF CELL NECROSIS AND METHODS OF PREPARATION OF THE SAME | |
| ECSP19066134A (en) | IMIDAZO [4,5-c] QUINOLIN-2-ONA DEUTERATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| CR20160558A (en) | COMPOSITE OF 1, 3, 4 - TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER | |
| CO2018010951A2 (en) | Cinnolin-4-amine compounds and their use in cancer treatment | |
| CO2021001925A2 (en) | Pyridopyrimidines as histamine h4 receptor inhibitors | |
| AR120626A1 (en) | SALTS OF AN FGFR INHIBITOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |